Develops blood tests that use chromosome-based markers to detect and monitor cancers and other diseases for human healthcare and veterinary use.
10-K for FY2025, filed Mar 31, 2026Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and…View ↗
The tests offered by Volition and its subsidiaries are designed to detect and monitor a range of life-altering diseases, including certain…View ↗
Nu.Q® Vet - cost-effective, easy-to-use blood tests for dogs and other companion animals. The Nu.Q® Vet Cancer Test is commercially…View ↗
Nu.Q® Cancer - from screening, diagnosis and staging, therapy decision, planning and treatment to monitoring response to treatment and…View ↗
Customers buy Nu.Q® Vet cancer tests, nucleosomes and research-use kits; Volition also earns money from laboratory work for third parties and licensing rights. Product sales are paid when goods ship, while lab and licensing revenue comes from services and rights provided under agreements.
10-K for FY2025, filed Mar 31, 2026The Company generates product revenues from the sale of its Nu.Q® Vet Cancer Test, from the sale of nucleosomes, and from the sale of…View ↗
The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is…View ↗
The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties under…View ↗
The Company includes revenue recognized from the licensing of certain rights to third parties in “Licensing” in the consolidated statements…View ↗
$1.7M
10-K for FY2025, filed Mar 31, 2026
$1.7M ↗
Veterinarians can obtain the dog cancer test through distributors, including Antech Diagnostics, IDEXX Laboratories and Fujifilm Vet Systems. Drug developers and scientists use Nu.Q® Discover assays and related research tools.
10-K for FY2025, filed Mar 31, 2026Our test can be easily integrated into preventive care programs and used alongside other routine bloodwork during regular wellness visits.…View ↗
Nu.Q® Discover is a complete solution to profiling nucleosomes which empowers drug developers and scientists, offering rapid epigenetic…View ↗
In addition to biomarkers we have developed and commercialized a High Throughput Model that measures Neutrophil Extracellular Traps “NETs”…View ↗
No. It lost $23.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$3.8MView ↗
8-K, filed Nov 12, 2026
On November 12, 2026, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business…View ↗
Growing. Revenue grew 19.2x in 4 years, from $90K in FY2021 to $1.7M in FY2025, about 109% a year.
Competes with Exact Sciences, Guardant Health, GRAIL, Natera, Caris Life Sciences, Freenome Holdings, CellMax Life, Archer DX, Foundation Medicine, Oncocyte, OpKo Health, MDNA Life Sciences, Abbott Laboratories, Cepheid, Hologic, Agilent Technologies, Qiagen, Thermo Fisher, Illumina, and Becton Dickinson
10-K for FY2025, filed Mar 31, 2026We face competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences…View ↗
Loading...